H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Actinium Pharmaceuticals (ATNM - Research Report) today and set a price target of $45.00. The company's shares closed yesterday at $7.66.According to TipRanks, Pantginis is an analyst with an average return of -23.4% and a 22.16% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Humanigen, Astria Therapeutics, and Krystal Biotech.The word on The Street in general, suggests a Strong Buy analyst consensus rating for Actinium Pharmaceuticals with a $25.60 average price target, a 234.20% upside from current levels.
https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-its-buy-rating-for-actinium-pharmaceuticals-atnm?utm_source=advfn.com&utm_medium=referral
Actinium Pharmaceuticals (AMEX:ATNM)
Historical Stock Chart
From Oct 2022 to Nov 2022 Click Here for more Actinium Pharmaceuticals Charts.
Actinium Pharmaceuticals (AMEX:ATNM)
Historical Stock Chart
From Nov 2021 to Nov 2022 Click Here for more Actinium Pharmaceuticals Charts.